Congenital myasthenic syndromes;Kongenitale myasthene syndrome

Nervenheilkunde

Volumn 30, Issue 10, 2011, Pages 797-804

  Della Marina, A ^a   Abicht, A ^b,c   Schara, Ulrike ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Medizinisch Genetisches Zentrum   (Germany)

Author keywords

Congenital myasthenic syndromes; Diagnostic work up; Genotype; Phenotype; Treatment

Indexed keywords

CLINICAL FEATURE; CONGENITAL MYASTHENIC SYNDROME; DIAGNOSTIC TEST; HUMAN; REVIEW;

EID: 80054057675     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Abicht A, Lochmüller H. Congenital myasthenic syndromes. In: Pagon RA et al. (eds). GeneReviews [Internet]. Seattle, WA: University of Washington 1993.
2. Agrov Z. Current approach to seronegative myasthenia. J Neurol 2011; 258: 14-18.
3. Colomer J et al. Long-term improvement of slowchannel congenital myasthenic syndrome with fluoxetine. Neuromuscul Disord 2006; 16: 329-333.
4. Barisic N et al. Clinical variability of CMS-EA (congenital myasthenic syndrome with episodic apnea) due to identical CHAT mutations in two infants. Eur J Paediatr Neurol 2005; 9(1): 7-12. (Pubitemid 40214764)
5. Engel AG, Sine SM. Current understanding of congenital myasthenic syndromes. Curr Opin Pharmacol 2005; 5(3): 308-21. (Pubitemid 40674255)
6. Engel AG, Shen XM, Selcen D, Sine SM. What have we learned from the congenital myasthenic syndroms. J Mol Neurosci 2010; 50: 143-153.
7. Hantaï D, Richard P, Koenig J, Eymard B. Congenital myasthenic syndromes. Curr Opin Neurol 2004; 17: 539-51. (Pubitemid 39410870)
8. Huzé C et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 2009; 85(2): 155-67.
9. Kinali M et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol 2008; 201-202: 6-12.
10. Lashley D, Palace J, Jayawant S, Robb S, Beeson D. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology 2010; 74(19): 1517-23.
11. Maselli RA et al. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. J Med Genet 2009; 46(3): 203-8.
12. Mihaylova V et al. Refinement of the clinical phenotype in musk-related congenital myasthenic syndromes. Neurology 2009; 73: 1926-8.
13. Müller JS, Mihaylova V, Abicht A, Lochmüller H. Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission. Expert Rev Mol Med 2007; 9: 1-20. (Pubitemid 47261141)
14. Müller JS et al. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain 2007; 130: 1497-506. (Pubitemid 47355920)
15. Schara U et al. Kongenitale myasthene Syndrome -vom Symptom zur Diagnose. Päd 2007; 13: 102-114.
16. Schara U, Lochmüller H. Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics 2008; 5: 542-547.
17. Schara U et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord 2009; 19: 828-32.
18. Schara U et al. Long-term follow-up in patients with congenital myasthenic syndrome due to CHAT mutations. Eur J Paediatr Neurol 2010; 14: 326-33.
19. Senderek J et al. Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect. Am J Hum Genet 2011; 88(2): 162-72.
20. Spillane J, Beeson J, Kullmann DM. Myasthenia and related disorders of the neuromuscular junction. J Neurol Neurosurg Psychiatry 2010; 81: 850-857.